Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM HONEYCUTT

NPI
1457340960
CMS profile
247917
Location
MAITLAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$87,598.97

292 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 4 of 6; records 151–200 of 292 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM HONEYCUTT

NPI 1457340960 · CMS profile ID 247917

MAITLAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 6; records 151–200 of 292 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457340960?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM HONEYCUTT, NPI 1457340960, CMS profile ID 247917. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 292 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457340960?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). WILLIAM HONEYCUTT, NPI 1457340960, CMS profile ID 247917. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 292 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457340960?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
WILLIAM HONEYCUTT, NPI 1457340960, CMS profile ID 247917, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 292 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1457340960?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

292 matching records · $87,598.97 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 292 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 292.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $21.1006/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827863717 CMS
UCB, Inc. $18.7806/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807375855 CMS
Horizon Therapeutics plc $115.6606/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797149947 CMS
Biohaven Pharmaceuticals, Inc. $23.6506/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852519689 CMS
Celgene Corporation $48.6406/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783703797 CMS
Celgene Corporation $3,120.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783703799 CMS
Celgene Corporation $711.9506/23/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783703801 CMS
EMD Serono, Inc. $48.5006/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849197893 CMS
Lilly USA, LLC $13.0006/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937119521 CMS
AbbVie Inc. $13.6606/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794856661 CMS
UPSHER-SMITH LABORATORIES LLC $24.9606/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834679713 CMS
Biogen, Inc. $124.8506/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827863699 CMS
Biogen, Inc. $34.4706/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827863701 CMS
GENZYME CORPORATION $17.3106/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843457379 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $2.0906/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814981955 CMS
AbbVie Inc. $975.0006/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794856657 CMS
Alexion Pharmaceuticals, Inc. $4.1606/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783123019 CMS
Allergan, Inc. $22.0306/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792806841 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $1.4706/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814981949 CMS
Neurelis, Inc. $12.6106/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842867263 CMS
Biogen, Inc. $90.2106/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827863687 CMS
Celgene Corporation $16.6506/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783703757 CMS
AbbVie Inc. $13.8306/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794856653 CMS
Celgene Corporation $124.3706/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783703759 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $0.8206/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814981943 CMS
Genentech USA, Inc. $12.7806/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835991803 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $1.4206/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814981937 CMS
Teva Pharmaceuticals USA, Inc. $23.3506/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839547207 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $16.9205/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814981929 CMS
Biogen, Inc. $16.1205/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827863715 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $51.3905/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814981835 CMS
Neurocrine Biosciences, Inc. $24.3705/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837796105 CMS
Neurocrine Biosciences, Inc. $24.3705/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837796107 CMS
Genentech USA, Inc. $2,435.0005/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835991821 CMS
Lundbeck LLC $22.0505/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845912699 CMS
Eisai Inc. $20.2605/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845775057 CMS
Allergan, Inc. $21.4805/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792806839 CMS
GENZYME CORPORATION $1,638.0005/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843457375 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $1.4305/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814981923 CMS
Biogen, Inc. $15.9005/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827863693 CMS
GENZYME CORPORATION $1,638.0005/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843457445 CMS
UCB, Inc. $15.1805/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807306357 CMS
Amgen Inc. $21.4405/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825877667 CMS
EMD Serono, Inc. $110.0005/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849180893 CMS
Genentech USA, Inc. $4.5605/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835991801 CMS
Teva Pharmaceuticals USA, Inc. $1.7905/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839547197 CMS
Teva Pharmaceuticals USA, Inc. $2.2105/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839547201 CMS
Teva Pharmaceuticals USA, Inc. $13.1205/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839547203 CMS
AbbVie Inc. $10.6005/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794856649 CMS
JAZZ PHARMACEUTICALS INC. $17.7305/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845627219 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $182,074.03 481
PY2020 $64,166.04 247
PY2021 $87,598.97 292
PY2022 $103,492.85 274
PY2023 $63,442.30 242
PY2024 $23,501.87 195
PY2025 $12,313.59 248

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $33,383.15 2
PY2025 Principal investigator $2,710,878.47 158
PY2024 Recipient $1,168.37 2
PY2024 Principal investigator $2,343,096.29 131
PY2023 Principal investigator $2,705,246.13 84
PY2022 Principal investigator $1,952,482.19 53
PY2021 Recipient $100.00 1
PY2021 Principal investigator $1,534,845.61 72
PY2020 Recipient $17,817.51 2
PY2020 Principal investigator $1,295,151.46 65
PY2019 Recipient $136,923.47 19
PY2019 Principal investigator $1,035,814.44 109

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

160 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $201.00 12/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES, PA
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis No dispute reported 06/30/2026 1190313927
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 12/19/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627528
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 12/19/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627531
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 12/19/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627537
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 12/19/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627540
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 12/19/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627545
Principal investigator 1 F. Hoffmann-La Roche AG $5,570.00 12/19/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627552
Principal investigator 1 Genentech, Inc. $4,186.00 12/19/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211627683
Principal investigator 1 Genentech, Inc. $8,226.00 12/16/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (PORTAMENTO) No dispute reported 06/30/2026 1211627580
Recipient Hexal AG $12,892.64 12/09/2025 Covered Recipient Physician CCYB704A12301 No dispute reported 06/30/2026 1186348484
Principal investigator 1 Genentech, Inc. $11,081.00 12/04/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211627643
Principal investigator 1 GENZYME CORPORATION $9,702.00 12/02/2025 Non-covered Recipient Entity
Neurology Associates, Pa
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226136135
Principal investigator 1 F. Hoffmann-La Roche AG $250.00 12/01/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627548
Principal investigator 1 Genentech, Inc. $10,698.00 11/25/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
OCARINA 3 No dispute reported 06/30/2026 1211627575
Principal investigator 1 Genentech, Inc. $2,093.00 11/25/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211627678
Principal investigator 1 Genentech, Inc. $1,383.00 11/20/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211627640
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 11/19/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627521
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 11/19/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627524
Principal investigator 1 F. Hoffmann-La Roche AG $5,570.00 11/19/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627534
Principal investigator 1 GENZYME CORPORATION $5,823.90 11/17/2025 Non-covered Recipient Entity
Neurology Associates, Pa
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226136125
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $250.00 11/07/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-1284-101 No dispute reported 06/30/2026 1242365871
Principal investigator 1 Genentech, Inc. $5,335.00 11/05/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211627670
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $250.00 11/05/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-214-202 No dispute reported 06/30/2026 1242365719
Principal investigator 1 GENZYME CORPORATION $57,120.00 11/04/2025 Non-covered Recipient Entity
Neurology Associates, Pa
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226136122
Principal investigator 1 Genentech, Inc. $9,995.00 10/29/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (PORTAMENTO) No dispute reported 06/30/2026 1211627567
Principal investigator 1 Genentech, Inc. $1,020.00 10/28/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
OCARINA 3 No dispute reported 06/30/2026 1211627571
Principal investigator 1 Genentech, Inc. $5,367.00 10/28/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211627636
Principal investigator 1 F. Hoffmann-La Roche AG $684.00 10/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627502
Principal investigator 1 F. Hoffmann-La Roche AG $5,570.00 10/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627506
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 10/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627511
Principal investigator 1 F. Hoffmann-La Roche AG $5,570.00 10/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627514
Principal investigator 1 F. Hoffmann-La Roche AG $5,570.00 10/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627518
Principal investigator 1 GENZYME CORPORATION $5,888.30 10/20/2025 Non-covered Recipient Entity
Neurology Associates, Pa
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226136116
Principal investigator 1 Genentech, Inc. $2,366.00 10/15/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211627674
Principal investigator 1 ABBVIE INC. $9,500.00 10/14/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202516753
Principal investigator 1 ABBVIE INC. $5,066.96 10/14/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202516755
Recipient Hexal AG $20,490.51 10/14/2025 Covered Recipient Physician CCYB704A12301 No dispute reported 06/30/2026 1186348486
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,065.00 10/02/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-214-202 No dispute reported 06/30/2026 1242359870
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,186.00 10/02/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-214-202 No dispute reported 06/30/2026 1242359872
Principal investigator 1 GENZYME CORPORATION $4,428.45 09/29/2025 Non-covered Recipient Entity
Neurology Associates, Pa
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226136090
Principal investigator 1 F. Hoffmann-La Roche AG $2,430.00 09/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627411
Principal investigator 1 F. Hoffmann-La Roche AG $2,430.00 09/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627425
Principal investigator 1 F. Hoffmann-La Roche AG $2,430.00 09/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627456
Principal investigator 1 F. Hoffmann-La Roche AG $2,430.00 09/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627459
Principal investigator 1 F. Hoffmann-La Roche AG $2,430.00 09/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627478
Principal investigator 1 F. Hoffmann-La Roche AG $2,430.00 09/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627482
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 09/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627486
Principal investigator 1 Genentech, Inc. $62,644.00 09/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211627618
Principal investigator 1 Genentech, Inc. $55,345.00 09/18/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211627667
Principal investigator 1 Genentech, Inc. $4,732.00 09/17/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211627663
Principal investigator 1 F. Hoffmann-La Roche AG $2,750.00 09/15/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627428
Principal investigator 1 F. Hoffmann-La Roche AG $250.00 09/15/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627442
Principal investigator 1 F. Hoffmann-La Roche AG $2,594.00 09/15/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627450
Principal investigator 1 F. Hoffmann-La Roche AG $5,500.00 09/15/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627474
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 09/15/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627490
Principal investigator 1 F. Hoffmann-La Roche AG $2,585.00 09/15/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627496
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,500.00 09/15/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-1284-101 No dispute reported 06/30/2026 1242358840
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,793.00 09/15/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-1284-101 No dispute reported 06/30/2026 1242358842
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,032.00 09/15/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-1284-101 No dispute reported 06/30/2026 1242358844
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,065.00 09/08/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-214-202 No dispute reported 06/30/2026 1242358700
Principal investigator 1 GENZYME CORPORATION $9,944.80 09/03/2025 Non-covered Recipient Entity
Neurology Associates, Pa
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226136070
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,269.22 09/01/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190305885
Principal investigator 1 Genentech, Inc. $11,377.00 08/27/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
OCARINA 3 No dispute reported 06/30/2026 1211627558
Principal investigator 1 Genentech, Inc. $97,630.00 08/20/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211627627
Principal investigator 1 Genentech, Inc. $2,758.00 08/20/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211627631
Principal investigator 1 Genentech, Inc. $14,832.00 08/15/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211627623
Principal investigator 1 Genentech, Inc. $6,720.00 08/13/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
OCARINA 3 No dispute reported 06/30/2026 1211627563
Principal investigator 1 GENZYME CORPORATION $77,492.00 08/11/2025 Non-covered Recipient Entity
Neurology Associates, Pa
Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226136059
Principal investigator 1 ABBVIE INC. $8,250.00 08/06/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202503609
Principal investigator 1 GENZYME CORPORATION $1,750.50 08/04/2025 Non-covered Recipient Entity
Neurology Associates, Pa
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226136040
Principal investigator 1 GENZYME CORPORATION $3,600.00 08/04/2025 Non-covered Recipient Entity
Neurology Associates, Pa
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226136043
Principal investigator 1 GENZYME CORPORATION $1,750.50 08/04/2025 Non-covered Recipient Entity
Neurology Associates, Pa
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226136048
Principal investigator 1 GENZYME CORPORATION $7,750.80 07/28/2025 Non-covered Recipient Entity
Neurology Associates, Pa
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226136052
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 07/23/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627398
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 07/23/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627403
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 07/23/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627408
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 07/23/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627414
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 07/23/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627418
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 07/23/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627421
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 07/23/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627431
Principal investigator 1 F. Hoffmann-La Roche AG $5,570.00 07/23/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627434
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 07/23/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627439
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 07/23/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627446
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 07/23/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627453
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 07/23/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627465
Principal investigator 1 F. Hoffmann-La Roche AG $2,594.00 07/23/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627469
Principal investigator 1 GENZYME CORPORATION $11,522.90 07/21/2025 Non-covered Recipient Entity
Neurology Associates, Pa
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226136300
Principal investigator 1 GENZYME CORPORATION $56,762.30 07/21/2025 Non-covered Recipient Entity
Neurology Associates, Pa
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226136302
Principal investigator 1 Genentech, Inc. $5,367.00 07/21/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211627614
Principal investigator 1 Genentech, Inc. $6,279.00 07/21/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211627658
Principal investigator 1 GENZYME CORPORATION $5,888.30 07/14/2025 Non-covered Recipient Entity
Neurology Associates, Pa
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226136318
Principal investigator 1 GENZYME CORPORATION $4,073.40 07/02/2025 Non-covered Recipient Entity
Neurology Associates, Pa
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226136295
Principal investigator 1 GENZYME CORPORATION $5,694.70 07/02/2025 Non-covered Recipient Entity
Neurology Associates, Pa
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226136322
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 06/20/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627363
Principal investigator 1 F. Hoffmann-La Roche AG $2,594.00 06/20/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627368
Principal investigator 1 F. Hoffmann-La Roche AG $2,594.00 06/20/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627381
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 06/20/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627395
Principal investigator 1 Hexal AG $11,211.75 06/17/2025 Non-covered Recipient Entity
Neurology Associates P.A.
CCYB704A12301 No dispute reported 06/30/2026 1186348910
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $721.00 06/04/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-214-202 No dispute reported 06/30/2026 1242348822
Principal investigator 1 Genentech, Inc. $20,260.00 06/03/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211627585
Principal investigator 1 Genentech, Inc. $2,366.00 05/21/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211627649
Principal investigator 1 GENZYME CORPORATION $2,762.40 05/19/2025 Non-covered Recipient Entity
Neurology Associates, Pa
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226136272
Principal investigator 1 Genentech, Inc. $21,966.60 05/14/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211627605
Principal investigator 1 Genentech, Inc. $49,481.00 05/13/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
OCARINA 3 No dispute reported 06/30/2026 1211627555
Principal investigator 1 Genentech, Inc. $5,367.00 05/09/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211627601
Principal investigator 1 Genentech, Inc. $4,137.00 05/02/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211627611
Principal investigator 1 F. Hoffmann-La Roche AG $2,594.00 04/25/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627372
Principal investigator 1 F. Hoffmann-La Roche AG $5,788.00 04/25/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627378
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 04/25/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627384
Principal investigator 1 F. Hoffmann-La Roche AG $2,594.00 04/25/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627387
Principal investigator 1 F. Hoffmann-La Roche AG $5,788.00 04/25/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627391
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,000.00 04/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190299968
Principal investigator 1 GENZYME CORPORATION $5,276.25 04/14/2025 Non-covered Recipient Entity
Neurology Associates, Pa
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226136241
Principal investigator 1 GENZYME CORPORATION $858.40 04/07/2025 Non-covered Recipient Entity
Neurology Associates, Pa
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226136184
Principal investigator 1 Genentech, Inc. $14,349.00 04/02/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211627654
Principal investigator 1 Novartis Pharmaceuticals Corporation $241,389.56 03/31/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190305893
Principal investigator 1 F. Hoffmann-La Roche AG $5,788.00 03/21/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627294
Principal investigator 1 F. Hoffmann-La Roche AG $2,594.00 03/21/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627301
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 03/21/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627314
Principal investigator 1 F. Hoffmann-La Roche AG $5,788.00 03/21/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627318
Principal investigator 1 F. Hoffmann-La Roche AG $5,788.00 03/21/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627330
Principal investigator 1 F. Hoffmann-La Roche AG $5,624.00 03/21/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627333
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 03/21/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627336
Principal investigator 1 F. Hoffmann-La Roche AG $5,788.00 03/21/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627347
Principal investigator 1 GENZYME CORPORATION $6,906.00 03/17/2025 Non-covered Recipient Entity
Neurology Associates, Pa
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226136175
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,065.00 03/07/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-214-202 No dispute reported 06/30/2026 1242334718
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,186.00 03/07/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-214-202 No dispute reported 06/30/2026 1242334720
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,497.00 03/07/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-214-202 No dispute reported 06/30/2026 1242334722
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,382.00 03/07/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-214-202 No dispute reported 06/30/2026 1242334724
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $721.00 03/07/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-214-202 No dispute reported 06/30/2026 1242334730
Principal investigator 1 Novartis Pharmaceuticals Corporation $357,514.40 03/05/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190305889
Principal investigator 1 GENZYME CORPORATION $1,921.70 03/04/2025 Non-covered Recipient Entity
Neurology Associates, Pa
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226136171
Principal investigator 1 ABBVIE INC. $2,343.51 02/27/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) No dispute reported 06/30/2026 1202455049
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,271.76 02/27/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES
A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy No dispute reported 06/30/2026 1190299960
Principal investigator 1 GENZYME CORPORATION $8,060.50 02/24/2025 Non-covered Recipient Entity
Neurology Associates, Pa
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226136180
Principal investigator 1 Genentech, Inc. $32,934.00 02/20/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211627593
Principal investigator 1 Genentech, Inc. $403.00 02/14/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211627589
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,065.00 02/07/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-214-202 No dispute reported 06/30/2026 1242330279
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,186.00 02/07/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-214-202 No dispute reported 06/30/2026 1242330281
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,295.00 02/07/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-214-202 No dispute reported 06/30/2026 1242330283
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,895.00 02/07/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-214-202 No dispute reported 06/30/2026 1242330285
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,697.00 02/07/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
ITI-214-202 No dispute reported 06/30/2026 1242330287
Principal investigator 1 Genentech, Inc. $10,250.00 02/04/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211627596
Principal investigator 1 Novartis Pharmaceuticals Corporation $38,499.14 01/28/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190299956
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,067.00 01/28/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190299964
Principal investigator 1 Novartis Pharmaceuticals Corporation $379,115.75 01/27/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES, PA
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190304187
Principal investigator 1 F. Hoffmann-La Roche AG $5,624.00 01/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627305
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 01/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627311
Principal investigator 1 F. Hoffmann-La Roche AG $5,624.00 01/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627322
Principal investigator 1 F. Hoffmann-La Roche AG $5,624.00 01/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627326
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 01/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627339
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 01/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627343
Principal investigator 1 F. Hoffmann-La Roche AG $5,624.00 01/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627350
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 01/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627355
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 01/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627360
Principal investigator 1 ABBVIE INC. $5,656.51 01/16/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202439817
Principal investigator 1 GENZYME CORPORATION $4,073.40 01/13/2025 Non-covered Recipient Entity
Neurology Associates, Pa
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226136200
Principal investigator 1 Novartis Pharmaceuticals Corporation $79,184.06 01/06/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190305891
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,554.00 01/01/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES, PA
A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy No dispute reported 06/30/2026 1190304189
Principal investigator 1 Novartis Pharmaceuticals Corporation $564,218.75 01/01/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES, PA
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190304191